share_log

Needham Reiterates Buy on Revolution Medicines, Maintains $46 Price Target

Benzinga ·  May 9 06:46

Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $46 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment